Open access
Oct 2026
Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in Multiple Sclerosis
This cohort study investigates if anti-CD20 treatment is associated with an increase in the risk of inflammatory bowel disease in individuals with multiple sclerosis (MS).
Sandra Kallin, A. Svenningsson, O. Olén et al.
· JAMA Neurology · 0 citations